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or their authorized representatives.
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Patients will be eligible if they meet the following criteria: 1) Age ≥18 years, 2) 11 clinical symptoms suggesting CAP (cough, fever, pleuritic chest pain or dyspnoea), 3) new chest radiographic infiltrate, 4) severe CAP criteria, defined by ATS criteria 13 modified by Ewig and co-workers or Pneumonia Severity Index (PSI) class V, and 5) 14 C-reactive protein (CRP) at admission >15 mg/dL. We choose 15 mg/dl based on the 15 observation of a higher percentage of treatment failures in this group in our database 16 of CAP collected in the three previous years (personal database observation).
17
Patients will be excluded from the study if one of the following criteria apply: All patients will be treated with antibiotics according to current international 33 guidelines. Switch from intravenous to oral therapy and duration of the antibiotic 34 treatment will be entirely left to the discretion of the medical team, as will be the 35 decisions to transfer patients to ICU or hospital discharge.
36

Definitions
37
The primary efficacy outcome is the rate of treatment failure stratified as early The following data will be collected on admission: age, gender, smoking 50 history, clinical symptoms, physical examination and co-morbidities. The initial risk 51 class will be calculated using the PSI and severity criteria will be assessed according 
77
Standard laboratory assessment performed at presentation will include renal 78 and liver functions, electrolytes, blood glucose, CRP, and haematology. Arterial 79 blood gases will be performed at admission and thereafter as clinically indicated.
80
Cytokines, procalcitonin and CRP determinations will be obtained on the first PCT; DiaSorin, Saluggia, Italy) with a detection limit of 0·3 ng/ml. CRP will be 86 measured with an immunoturbidimetric method using a commercially available test
87
(Bayer Diagnostics, Leverkusen, Germany) with an Advia 2400.
88
Adverse events during hospital stay will be carefully monitored and classified
89
as being possibly related to corticosteroids (hyperglycemia, super-infection, 90 gastrointestinal bleeding, and delirium) or not.
91
Statistical analysis
92
The study is based on the assumption that the placebo group would have a analyses, we will perform logistic regression models to examine differences in 109 primary outcome and in-hospital mortality between the two groups. We will also 110 assess differences in secondary outcomes between both treatment groups with Cox
111
proportional hazard regression models. The primary and secondary outcomes will significance is set at 5%. All analyses will be performed with SPSS 15 or later.
